FDA written feedback supports:- a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS- a randomized vs ...

m project drew outrage over ethical questions about withholding vaccines proven to prevent disease ...

Data suggest that when pharmacological Zn levels used, average daily gain and average daily feed intake can be improved with ...

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...

Although a 2024 collab produced one of the best LEGO sets in recent memory, even the most hardcore fans may never complete ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of ...

Larian Studios head of design Nick Pechenin stepped in to answer a question about Divinity's loot system, explaining that the ...

Survive in the ancient clockwork world of Elysium in this airship survival RPG set in the heavens of mythical ancient Greece.

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

With Persona 3 Reload and Persona 5 Royal released, we rank the 12 best Persona games to see how the classics stack up ...

From physics-based city builders to time-traveling medieval battles, these games will let you unleash your creativity in the ...

Atara Biotherapeutics (NASDAQ: ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD).